The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
暂无分享,去创建一个
[1] R. Wynn,et al. Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family* , 1999, The Journal of Biological Chemistry.
[2] E. Rubenstein,et al. Scientific American Medicine , 1985 .
[3] H. Ploegh,et al. Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages , 2000, The Journal of experimental medicine.
[4] R. DesJarlais,et al. Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K. , 1999, Bioorganic & medicinal chemistry letters.
[5] Yong Wang,et al. Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. , 2002, Journal of medicinal chemistry.
[6] P. Libby,et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.
[7] D. Yamashita,et al. Cathepsin K and the design of inhibitors of cathepsin K. , 2000, Current pharmaceutical design.
[8] J. Falgueyret,et al. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. , 2003, Journal of medicinal chemistry.
[9] H. Kirschke,et al. Cathepsin S. The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15). , 1986, The Biochemical journal.
[10] Y. Fujisawa,et al. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. , 1998, Journal of medicinal chemistry.
[11] S. Carr,et al. Structure and Design of Potent and Selective Cathepsin K Inhibitors , 1997 .
[12] R. Bohacek,et al. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. , 2001, Journal of medicinal chemistry.
[13] A. Rudensky,et al. Lysosomal cysteine proteases regulate antigen presentation , 2003, Nature Reviews Immunology.
[14] J. Deussing,et al. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. H. Drummond,et al. Metalloproteinase inhibitors as therapeutics. , 1993, Clinical and experimental rheumatology.
[16] A. Roessner,et al. Expression of cathepsin K in the human embryo and fetus , 1999, Developmental dynamics : an official publication of the American Association of Anatomists.
[17] E. Vuorio,et al. Accelerated Turnover of Metaphyseal Trabecular Bone in Mice Overexpressing Cathepsin K , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] A. Silman,et al. Epidemiology and genetics of rheumatoid arthritis , 2002, Arthritis research.
[19] R. Mitchell,et al. Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.
[20] R. DesJarlais,et al. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K. , 1998, Journal of medicinal chemistry.
[21] S. Abramson. Et tu, acetaminophen? , 2002, Arthritis and rheumatism.
[22] E. Shaw. Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. , 1994, Methods in enzymology.
[23] W. Jahnke,et al. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. , 2002, Journal of medicinal chemistry.
[24] D. Heinegård,et al. Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy. , 1988, The Biochemical journal.
[25] Bonnie F. Sloane,et al. Cysteine proteases and tumor progression , 1995 .
[26] R. Maciewicz,et al. Cathepsin L‐deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy , 2004, International journal of experimental pathology.
[27] Lynda J Martin,et al. Rheumatoid arthritis: symptoms, diagnosis, and management. , 2004, Nursing times.
[28] J. Delaissé,et al. Cysteine Proteinases and Matrix Metalloproteinases Play Distinct Roles in the Subosteoclastic Resorption Zone , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] C. Debouck,et al. Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.
[30] J. Palmer,et al. The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant induced arthritis. , 1993, The Journal of rheumatology.
[31] P. Roughley,et al. Link protein as a monitor in situ of endogenous proteolysis in adult human articular cartilage. , 1991, The Biochemical journal.
[32] P. Saftig,et al. The Bone Lining Cell: Its Role in Cleaning Howship's Lacunae and Initiating Bone Formation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] S. Weiss,et al. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Rich,et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.
[35] A. Barrett,et al. Action of rat liver cathepsin L on collagen and other substrates. , 1982, The Biochemical journal.
[36] D. N. Deaton,et al. Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications. , 2004, Journal of Medicinal Chemistry.
[37] R. Wynn,et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.
[38] J. Pelletier,et al. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. , 1997, Arthritis and rheumatism.
[39] Jeffrey D Peterson,et al. The design of potent hydrazones and disulfides as cathepsin S inhibitors. , 2003, Bioorganic & medicinal chemistry.
[40] N. Horiuchi,et al. Induction of collagenase-2 (matrix metalloproteinase-8) gene expression by interleukin-1beta in human gingival fibroblasts. , 2001, Journal of periodontal research.
[41] D. Brömme,et al. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. , 2002, Chemical reviews.
[42] Lars Karlsson,et al. Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.
[43] J. Smolen,et al. DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. , 2003, Clinical and experimental rheumatology.
[44] M. Mcgrath. The lysosomal cysteine proteases. , 1999, Annual review of biophysics and biomolecular structure.
[45] A. Thiel,et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. , 2003, Arthritis and rheumatism.
[46] Vincent Leroy,et al. Cathepsin S inhibitors , 2004 .
[47] J. McKerrow,et al. Cysteine protease inhibitors as chemotherapy for parasitic infections. , 1999, Bioorganic & medicinal chemistry.
[48] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[49] L. Jacobsson,et al. Osteoarthritis of the peripheral joints. , 2002, Best practice & research. Clinical rheumatology.
[50] J. Deussing,et al. Proteases involved in MHC dass II antigen presentation , 1999, Immunological reviews.
[51] T. Hardingham,et al. Proteoglycans: many forms and many functions , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] C. Brinckerhoff,et al. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.
[53] Makoto Naito,et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.
[54] S. Stevanović,et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. , 2003, The Journal of clinical investigation.
[55] J G Gleason,et al. Design of potent and selective human cathepsin K inhibitors that span the active site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[56] B. Bresnihan,et al. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.
[57] G. Mundy. Osteoporosis: pathophysiology and non-pharmacological management. , 2001, Best practice & research. Clinical rheumatology.
[58] E. Boyce,et al. The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic Cancers , 1999, The Annals of pharmacotherapy.
[59] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[60] H. Ploegh,et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. , 1996, Immunity.
[61] A. Barrett,et al. Cathepsin B1. A lysosomal enzyme that degrades native collagen. , 1974, The Biochemical journal.
[62] J. Kopeček,et al. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. , 2002, Biochemistry.
[63] W. Parks,et al. Collagenase-1 and collagen in epidermal repair , 1998, Archives of Dermatological Research.
[64] J. Ellman,et al. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. , 2002, Journal of medicinal chemistry.
[65] A. Rudensky,et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.
[66] T. Schirmeister,et al. Cysteine Proteases and Their Inhibitors. , 1997, Chemical reviews.
[67] V. Danis,et al. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide‐induced interleukin‐1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis , 1990, Clinical and experimental immunology.
[68] L. Moreland,et al. Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. , 1999, Arthritis care and research : the official journal of the Arthritis Health Professions Association.
[69] Y. Ru,et al. Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro * , 2001, The Journal of Biological Chemistry.
[70] B. Jarvis,et al. Leflunomide , 1999, Drugs.
[71] B. Gelb,et al. Cathepsin K Deficiency in Pycnodysostosis Results in Accumulation of Non-Digested Phagocytosed Collagen in Fibroblasts , 2003, Calcified Tissue International.
[72] M. Karsdal,et al. Proteinases in bone resorption: obvious and less obvious roles. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[73] R. DesJarlais,et al. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic. , 1998, Journal of medicinal chemistry.
[74] I. Reid. The roles of calcium and vitamin D in the prevention of osteoporosis. , 1998, Endocrinology and metabolism clinics of North America.
[75] D. Brömme,et al. Human Cathepsin O2, a Matrix Protein-degrading Cysteine Protease Expressed in Osteoclasts , 1996, The Journal of Biological Chemistry.
[76] M. Zawadzka,et al. Molecular mechanisms of neuroprotective action of immunosuppressants ‐ facts and hypotheses , 2004, Journal of cellular and molecular medicine.
[77] P. Roughley,et al. Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. , 1990, The Biochemical journal.
[78] Y. Ru,et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. , 2002, Bone.
[79] N. Ishimaru,et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. , 2002, The Journal of clinical investigation.
[80] C. Bayly,et al. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[81] J. Mort,et al. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. , 1998, The Biochemical journal.
[82] R. Gordon,et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.
[83] S. Santavirta,et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. , 2002, Arthritis and rheumatism.
[84] D. Turk,et al. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo. , 2000, Biochemical and biophysical research communications.
[85] K. Korach,et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.
[86] B. Gelb,et al. Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.
[87] A. Hollander,et al. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. , 1997, Arthritis and rheumatism.
[88] R. Fox,et al. Mechanism of action of hydroxychloroquine as an antirheumatic drug. , 1993, Seminars in arthritis and rheumatism.
[89] Mary Pat Beavers,et al. Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.
[90] E. Eriksen,et al. European and North American Experience with HRT for the prevention of osteoporosis. , 1996, Bone.
[91] Teruo Tanaka,et al. Cathepsins in the osteoclast. , 2003, Journal of electron microscopy.
[92] M. Kumegawa,et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. , 1994, The Journal of biological chemistry.
[93] Sheila J. Jones,et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[94] A. Hollander,et al. Molecular Interaction and Matrix Assembly , 1998, The Biochemical journal.
[95] B. Caterson,et al. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. , 1998, Osteoarthritis and cartilage.
[96] J. Vane,et al. The mechanism of action of aspirin. , 2003, Thrombosis research.
[97] G. Obeid,et al. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. , 2005, Journal.
[98] M. Bogyo,et al. Regulation of Collagenase Activities of Human Cathepsins by Glycosaminoglycans* , 2004, Journal of Biological Chemistry.
[99] T. Welte,et al. Expression of cathepsin K in lung epithelial cells. , 1999, American journal of respiratory cell and molecular biology.
[100] L. Shewchuk,et al. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. , 2004, Journal of medicinal chemistry.
[101] E. Purisima,et al. 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[102] S. Goldring,et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. , 2002, Arthritis and rheumatism.
[103] Ranjeny Thomas,et al. Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis? , 1999, Immunology and cell biology.
[104] D. Brömme,et al. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. , 2000, Biochemistry.
[105] Y. Ru,et al. Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[106] G. Dranoff,et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.
[107] H. Tsuge,et al. Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells. , 2002, Archives of biochemistry and biophysics.
[108] P. Emery,et al. Role of biologics in early arthritis. , 2003, Clinical and experimental rheumatology.
[109] P. Cresswell. Invariant Chain Structure and MHC Class II Function , 1996, Cell.
[110] Dayer Jm,et al. Leflunomide: mode of action in the treatment of rheumatoid arthritis , 2000, Annals of the rheumatic diseases.
[111] D. Fairlie,et al. Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.
[112] A. Hall,et al. Control of matrix synthesis in isolated bovine chondrocytes by extracellular and intracellular pH , 1995, Journal of cellular physiology.
[113] D. Veber,et al. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors. , 2004, The journal of peptide research : official journal of the American Peptide Society.
[114] D. Brömme,et al. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. , 2002, Current pharmaceutical design.
[115] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[116] K. Hirohata,et al. Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro. , 1988, Arthritis and rheumatism.
[117] G. FitzGerald. Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.
[118] D. Brömme,et al. Cleavage Site Specificity of Cathepsin K toward Cartilage Proteoglycans and Protease Complex Formation , 2003, Biological chemistry.
[119] B. Gelb,et al. Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.
[120] L. Polgár,et al. Current problems in mechanistic studies of serine and cysteine proteinases. , 1982, The Biochemical journal.
[121] V. Everts,et al. Effects of the proteinase inhibitors leupeptin and E-64 on osteoclastic bone resorption , 1988, Calcified Tissue International.
[122] R. Bräuer,et al. Matrix metalloproteinases, IL-6, and nitric oxide in rat antigen-induced arthritis. , 1998, Clinical and experimental rheumatology.
[123] J. Palmer,et al. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. , 1994, Arthritis and rheumatism.
[124] A. Rudensky,et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.
[125] C. Peters,et al. Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. , 1993, The Journal of biological chemistry.
[126] Stanley B. Cohen,et al. An update on bisphosphonates , 2004, Current rheumatology reports.
[127] F. Tavares,et al. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K. , 2004, Journal of medicinal chemistry.
[128] C. Rorabeck,et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.
[129] B. Cronstein,et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. , 1996, Journal of immunology.
[130] G. Guyatt,et al. VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis , 2002 .
[131] B. Cronstein,et al. Molecular action of methotrexate in inflammatory diseases , 2002, Arthritis research.
[132] J. Pelletier,et al. The role of cytokines in osteoarthritis pathophysiology. , 2002, Biorheology.
[133] D. Turk,et al. Lysosomal cysteine proteases: facts and opportunities , 2001, The EMBO journal.
[134] J. Palmer,et al. Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.
[135] C. Brinckerhoff. Joint destruction in arthritis: metalloproteinases in the spotlight. , 1991, Arthritis and rheumatism.
[136] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[137] L. Lohmander,et al. Aggrecan degradation in osteoarthritis and rheumatoid arthritis. , 1995, Acta orthopaedica Scandinavica. Supplementum.
[138] M. Chopp,et al. A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia , 2001, Brain Research.
[139] P. Delmas,et al. The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.
[140] Y. Ru,et al. Cyclic ketone inhibitors of the cysteine protease cathepsin K. , 2001, Journal of medicinal chemistry.
[141] J. Kopeček,et al. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. , 2004, International journal of pharmaceutics.
[142] D. Felson,et al. Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.
[143] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[144] Y. Ru,et al. Azepanone-based inhibitors of human and rat cathepsin K. , 2001, Journal of medicinal chemistry.
[145] E. Purisima,et al. 6-Acylamino-penam derivatives: synthesis and inhibition of cathepsins B, L, K, and S. , 2002, Bioorganic & medicinal chemistry letters.
[146] V. Everts,et al. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis , 2007, Calcified Tissue International.
[147] J. Falgueyret,et al. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. , 2001, Journal of medicinal chemistry.
[148] D. Brömme,et al. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. , 1995, Biological chemistry Hoppe-Seyler.
[149] J. Weidner,et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. , 1997, The Journal of clinical investigation.
[150] R A Smith,et al. Discovery and parallel synthesis of a new class of cathepsin K inhibitors. , 2001, Bioorganic & medicinal chemistry letters.
[151] H. Ploegh,et al. Proteolysis in MHC class II antigen presentation: who's in charge? , 2000, Immunity.
[152] D. Turk,et al. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo , 1999, FEBS letters.
[153] J. Palmer,et al. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.